Bolt Biotherapeutics is a clinical-stage biotechnology company based in the San Francisco Bay Area, dedicated to developing Boltbody™ Immune-stimulating Antibody Conjugates (ISACs), a cutting-edge class of immuno-oncology therapeutics. The company’s mission centers on transforming cancer treatment and improving the lives of individuals facing this disease. Bolt Biotherapeutics emphasizes collaboration among multidisciplinary teams, including scientists and clinicians, to advance drug development from early-stage research through clinical trials. Core values reflected in their work culture include a commitment to scientific rigor, innovation, and a supportive environment that fosters professional growth and groundbreaking solutions in cancer therapy.